What do systematic reviews say?

Statins vs placebo or usual care

Statin therapy leads to lower major cardiovascular events (MACE) compared with placebo or standard of care (high certainty).

• HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis 2023 · Cochrane Headline outcomes only
  RR 0.72 [0.66, 0.79]
  14 studies · 36156 participants
  High

Statins vs placebo or usual care

Statin therapy leads to lower death compared with placebo or standard of care (high certainty).

• HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis 2023 · Cochrane Headline outcomes only
  RR 0.83 [0.73, 0.96]
  13 studies · 34978 participants
  High

Statins vs placebo or usual care

It is very uncertain whether statin therapy changes rhabdomyolysis compared with placebo or standard of care (very low certainty).

• HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis 2023 · Cochrane Headline outcomes only
  RR 3.07 [0.13, 75.37]
  2 studies · 2618 participants
  Very low

Statins vs placebo or usual care

Statin therapy probably leads to lower myocardial infarction compared with placebo or standard of care (moderate certainty).

• HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis 2023 · Cochrane Headline outcomes only
  RR 0.55 [0.42, 0.73]
  10 studies · 9475 participants
  Moderate

Statins vs placebo or usual care

Statin therapy showed no clear difference in stroke compared with placebo or standard of care (moderate certainty).

• HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis 2023 · Cochrane Headline outcomes only
  RR 0.64 [0.37, 1.08]
  7 studies · 9158 participants
  Moderate

Statins vs placebo or usual care

Statin therapy showed no clear difference in kidney failure compared with placebo or standard of care (moderate certainty).

• HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis 2023 · Cochrane Headline outcomes only
  RR 0.98 [0.91, 1.05]
  3 studies · 6704 participants
  Moderate

Statins vs placebo or usual care

Statin therapy showed no clear difference in hospitalisation due to heart failure compared with placebo or standard of care (low certainty).

• HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis 2023 · Cochrane Headline outcomes only
  RR 0.7 [0.37, 1.32]
  1 study · 579 participants
  Low

Intervention not reported

The intervention showed no clear difference in acute kidney injury (low certainty).

• HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac… 2015 · Cochrane Headline outcomes only
  RR 0.76 [0.46, 1.28]
  5 studies · 467 participants
  Low

Intervention not reported

• HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 195 participants
  Low

Intervention not reported

It is very uncertain whether the intervention changes renal replacement therapy (very low certainty).

• HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac… 2015 · Cochrane Headline outcomes only
  RR 0.8 [0.23, 2.81]
  2 studies · 251 participants
  Very low

Intervention not reported

It is very uncertain whether the intervention changes mortality (very low certainty).

• HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac… 2015 · Cochrane Headline outcomes only
  RR 3.86 [0.43, 34.4]
  5 studies · 381 participants
  Very low

Intervention not reported

It is very uncertain whether the intervention changes adverse events (very low certainty).

• HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac… 2015 · Cochrane Headline outcomes only
  RR 1.13 [1.47, 2.68]
  1 study · 140 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in major cardiovascular events (low certainty).

• HMG CoA reductase inhibitors (statins) for kidney transplant recipients 2014 · Cochrane Headline outcomes only
  RR 0.84 [0.66, 1.06]
  1 study · 2102 participants
  Low

Intervention not reported

The intervention showed no clear difference in all‐cause mortality (low certainty).

• HMG CoA reductase inhibitors (statins) for kidney transplant recipients 2014 · Cochrane Headline outcomes only
  RR 1.08 [0.63, 1.83]
  6 studies · 2760 participants
  Low

Intervention not reported

The intervention showed no clear difference in cardiovascular mortality (low certainty).

• HMG CoA reductase inhibitors (statins) for kidney transplant recipients 2014 · Cochrane Headline outcomes only
  RR 0.68 [0.45, 1.01]
  4 studies · 2322 participants
  Low

Intervention not reported

The intervention showed no clear difference in major cardiovascular events (high certainty).

• HMG CoA reductase inhibitors (statins) for dialysis patients 2013 · Cochrane Headline outcomes only
  RR 0.95 [0.88, 1.03]
  4 studies · 7804 participants
  High

Intervention not reported

The intervention showed no clear difference in all‐cause mortality (moderate certainty).

• HMG CoA reductase inhibitors (statins) for dialysis patients 2013 · Cochrane Headline outcomes only
  RR 0.96 [0.9, 1.02]
  13 studies · 4705 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in cardiovascular mortality (moderate certainty).

• HMG CoA reductase inhibitors (statins) for dialysis patients 2013 · Cochrane Headline outcomes only
  RR 0.94 [0.84, 1.06]
  13 studies · 4627 participants
  Moderate